PLAY PODCASTS
Key PBC Studies From AASLD 2024
Episode 426

Key PBC Studies From AASLD 2024

Hear key findings from clinical trials on PBC presented at AASLD 2024, including updated results from ELATIVE, RESPONSE, and ASSURE trials.

Decera Clinical Education Infectious Disease Podcast · Sonal Kumar MD MPH

January 7, 202520m 16s

Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

In this episode, Sonal Kumar, MD, MPH, discusses key findings from primary biliary cholangitis (PBC) studies presented at AASLD 2024, including:

  • ELATIVE, a phase III trial of elafibranor for PBC
  • RESPONSE, a phase III trial of seladelpar for PBC
  • ASSURE, another phase III trial of seladelpar for PBC

Presenter:
Sonal Kumar, MD, MPH
Director, Clinical Gastroenterology and Hepatology
Assistant Professor of Medicine
Weill Cornell Medical College
New York, New York

Link to full program:
https://bit.ly/41tvSDu

Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Topics

cirrhosiselative oleelafibranorseladelparprimary biliary cholangitisaasld 2024elativeresponsebilirubinpruritusopen-label extensionpbcassure